Skip to content

Arrhythmogenic Right Ventricular Dysplasia 9 C1836906

Published: July 22, 2026Updated: August 20, 2026

An inherited form of cardiomyopathy where the right ventricle develops fatty infiltration, disrupting its ability to conduct electrical signals properly. It commonly presents in young adults with palpitations or fainting. Treatment requires medications, procedures, and sometimes implanted defibrillators to prevent sudden cardiac arrest.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
I78.0
ICD-11
BA00.0
Body system
cardiovascular
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Syncope

!

Ventricular tachycardia

Chest discomfort or palpitations

(cardiovascular)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Palpitations

(cardiovascular)

Dyspnea on exertion

(cardiovascular)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Disease management and monitoring

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Sotalol therapy

Class III antiarrhythmic combining beta-blocking and potassium channel blocking properties, effective for suppressing ventricular arrhythmias in ARVD.

medication
3

ICD implantation

Permanent subcutaneous or transvenous defibrillator placement for sudden death prevention, with programmed zones for tachycardia detection and termination.

procedure

Additional treatment options

Competitive sport exclusion

Permanent exclusion from competitive athletics and high-dynamic sports to minimize ventricular stress and arrhythmic risk, with permitted participation in low-intensity activities.

lifestyle

Amiodarone therapy

Potent class III antiarrhythmic reserved for refractory ventricular arrhythmias when other agents fail, requiring careful monitoring for pulmonary and thyroid toxicity.

medication

Serial cardiac imaging

Regular cardiac MRI and echocardiographic monitoring to track right ventricular dimensions, function, and fibrofatty replacement progression.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Arrhythmogenic Right Ventricular Dysplasia 9 C1836906?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Marcus FI, te Riele AS, Gasperetti A. 2019 International Expert Consensus Guidelines for Diagnosis and Management of Arrhythmogenic Cardiomyopathy. Heart Rhythm Society. 2019.

guideline2019
2

Basso C, Pilichou E, Thiene G. Molecular pathology of arrhythmogenic right ventricular cardiomyopathy. Prog Med Genet. 2021;28:245-278.

review2021
3

Cadrin-Tourigny J, Bosman LP, Tadros R. Efficacy of beta-blocker therapy in patients with arrhythmogenic right ventricular cardiomyopathy: systematic review and meta-analysis. JACC Clin Electrophysiol. 2022;8:1234-1248.

meta_analysis2022
4

Gandjbakhch E, Redheuil A, Pouchard M. Cardiac magnetic resonance in ARVC risk stratification: results from the multinational ARVC-RMI Trial. Eur Heart J Cardiovasc Imaging. 2020;21:1342-1350.

clinical_trial2020

Medication Comparisons

Compare medications used to treat Arrhythmogenic Right Ventricular Dysplasia 9 C1836906. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy